- Home
- RDIB vs CVRX Comparison
RDIB vs CVRX Comparison
Compare RDIB & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | CVRX |
|---|---|---|
| Founded | 1937 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.2M | 221.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDIB | CVRX |
|---|---|---|
| Price | $11.15 | $8.01 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.17 |
| AVG Volume (30 Days) | 5.2K | ★ 157.4K |
| Earning Date | 03-30-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $211,292,000.00 | $55,969,000.00 |
| Revenue This Year | $1.06 | $11.49 |
| Revenue Next Year | $10.97 | $16.26 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.11 | ★ 18.44 |
| 52 Week Low | $5.78 | $4.30 |
| 52 Week High | $14.95 | $18.55 |
Technical Indicators
Market Signals| Indicator | RDIB | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 34.43 |
| Support Level | $10.88 | $8.07 |
| Resistance Level | $11.56 | $8.44 |
| Average True Range (ATR) | 0.48 | 0.58 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 31.28 | 11.21 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.